Drug
Bcx7353
Bcx7353: highest development phase Phase 3, developed by BioCryst Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| BCX7353 capsules NCT03873116 | Phase 3 | Hereditary Angioedema, HAE |
| BCX7353 capsules NCT03485911 | Phase 3 | Hereditary Angioedema |
| BCX7353 NCT03472040 | Phase 2/3 | Hereditary Angioedema |
| BCX7353 NCT03202784 | Phase 1 | Hereditary Angioedema |
| BCX7353 NCT02448264 | Phase 1 | Hereditary Angioedema |
Latest
No recent events.
Follow Bcx7353 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.